Sequence

Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development

Retrieved on: 
Mercoledì, Marzo 27, 2024
Sequence, Sequence analysis, Automation, Quality control, Logic, Database, Algorithm, Communication, Intelligence, Printing, Biomedical Research, Digitalization, Sequence alignment, Acceleration, Internet, Research, ELISA, Artificial intelligence, Software, PTM, Record, Molecular biology, CDE, Thought, Hook effect, Investment, Drug development, Telephone numbers in Hungary, Literature, Digital technology, EC50, Collection, Data management, Marketing, FDA, Parallel, Map, Mobile phone

This is the driving force behind Sanyou's development of an intelligence-enabled innovative biologics R&D platform.

Key Points: 
  • This is the driving force behind Sanyou's development of an intelligence-enabled innovative biologics R&D platform.
  • This system finds extensive applications across various domains, including research and development, data management, project management, quality control, and marketing.
  • By optimizing drug development processes and supporting intelligence-enabled decision-making, it comprehensively enhances R&D efficiency and accuracy, potentially playing a critical role in drug development.
  • In drug development, the modeling and prediction of drug developability analysis aims to comprehensively enhance the efficiency of the drug development process.

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Venerdì, Marzo 1, 2024
Sequence, Composition, Liver, RHO, Immunotherapy, Investment, FDA, Research and development, HSC, Food, CGD, Patent, SCIP, Lung, Ataxia, Cystic Fibrosis Foundation, Hematology, Administration, Patient, Target, IND, AAV, CTA, Pharmaceutical industry

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.

Key Points: 
  • “In 2024, we anticipate undergoing a significant transformation, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients.
  • This funding will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
  • Gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
  • In January 2024, Prime Medicine announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer.

WW International, Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Sequence, Acquisition, Republic of Ireland, Forecasting, Strategic planning, Digital, Nature, Workshop, Income tax, GAAP, Webcast, Depreciation, Tax, Hand, Wind, Music

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the fourth quarter and full year fiscal 2023.

Key Points: 
  • Total Paid Weeks in fiscal 2023 were down 3.9% versus the prior year, driven by declines in the Digital and Workshops + Digital businesses.
  • Adjusted gross profit in fiscal 2023, which excluded the net impact of $21.2 million of restructuring charges, was $550.5 million.
  • 2023 Restructuring Plan: In connection with the previously announced 2023 restructuring plan, the Company recorded aggregate restructuring charges of $23.1 million in Q4 2023.
  • In addition, the Company presents certain of its financial results on a constant currency basis in addition to GAAP results.

iDirect Government CSIR™ Technology Named Finalist for Via Satellite’s 2023 Satellite Technology of the Year Award

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Sequence, CSIR, SDR, Government, SATCOM, Radio, DSSS, Modem, Software, Communications satellite

HERNDON, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- iDirect Government (iDirectGov), a leading provider of satellite communications to the military and government, today announced that its Communication Signal Interference Removal (CSIR™) technology has been named a finalist for the 2023 Satellite Technology of the Year Award organized by Via Satellite.

Key Points: 
  • HERNDON, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- iDirect Government (iDirectGov), a leading provider of satellite communications to the military and government, today announced that its Communication Signal Interference Removal (CSIR™) technology has been named a finalist for the 2023 Satellite Technology of the Year Award organized by Via Satellite.
  • CSIR enhancements that are critical to support advanced signal excision were developed through the company’s Electronic Warfare Engineering Center of Excellence.
  • “CSIR’s new set of capabilities, including anti-jam technology, ensures that satellite connectivity and communications are safeguarded from interference.
  • The winner will be announced at SATELLITE 2024 on Wednesday, March 20, at the Via Satellite Awards luncheon.

RIOS Intelligent Machines Announces Successful Completion of $13 Million Series B Funding Round

Retrieved on: 
Martedì, Marzo 5, 2024
Other Manufacturing, Technology, Venture Capital, Other Technology, Professional Services, Manufacturing, Machinery, Robotics, Artificial Intelligence, Sequence, Partnership, Yamaha Motor Company, P-3, Navy, Yamaha, AI, Growth, IAG, Automation

RIOS Intelligent Machines , a leader in AI-powered robotics for the manufacturing industry, is excited to announce the successful completion of a $13 million Series B funding round.

Key Points: 
  • RIOS Intelligent Machines , a leader in AI-powered robotics for the manufacturing industry, is excited to announce the successful completion of a $13 million Series B funding round.
  • Since 2020, Yamaha Motor Corporation has been a steadfast investor in RIOS.
  • Their decision to co-lead this round alongside IAG Capital Partners highlights their confidence in RIOS's technology, team, and growing customer attraction.
  • This new round of funding will fuel RIOS's growth in three key industry segments: wood products, beverage distribution, and packaged food products.

Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences

Retrieved on: 
Giovedì, Febbraio 22, 2024
Health, Stem Cells, Health Technology, Genetics, Research, Science, Biotechnology, Promega, Sigma-Aldrich, CRISPR, Doctor of Philosophy, Sequence, Marketing, QIAGEN Silicon Valley, QIAGEN, Antibody, Biofuel, Biology, DNA

Ansa Biotechnologies, Inc. , a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer.

Key Points: 
  • Ansa Biotechnologies, Inc. , a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer.
  • Gammack is joining the company as it completes its early access program for complex synthetic genes and gene fragments and prepares for a full commercial service launch.
  • Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer.
  • Ansa’s proprietary DNA synthesis platform is based on precise enzymatic reagents that enable ultra-rapid and controlled single-base additions to a DNA molecule.

OpenFold Biotech AI Research Consortium releases SoloSeq and Multimer, an integrated protein Large Language Model with 3D structure generation

Retrieved on: 
Lunedì, Febbraio 19, 2024
Technology, Research, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Sequence, Transformer, DeepMind, Meta AI, Internet, Amazon Web Services, Architecture, MSA, Artificial intelligence, Multimedia, Bayer, AF2, De novo, Nature, ChatGPT, Structural biology, LLM, Computation, University, Meta, PDB, ESM, Organization, Protein, Columbia University, Agriculture, Deep learning, Google Brain, AWS

OpenFold , a non-profit artificial intelligence (AI) research consortium, today announced the release of two new tools: 1) SoloSeq, which integrates a new protein Large Language Model (LLM) with its OpenFold structure prediction software, and 2) OpenFold-Multimer software, which creates higher quality models of protein/protein complexes than OpenFold alone.

Key Points: 
  • OpenFold , a non-profit artificial intelligence (AI) research consortium, today announced the release of two new tools: 1) SoloSeq, which integrates a new protein Large Language Model (LLM) with its OpenFold structure prediction software, and 2) OpenFold-Multimer software, which creates higher quality models of protein/protein complexes than OpenFold alone.
  • The new Multimer code is the first fully open source training code system for the generation of protein/protein structures.
  • View the full release here: https://www.businesswire.com/news/home/20240219658831/en/
    OpenFold SoloSeq model prediction vs experimentally resolved structure for PDB protein 4B9Z (Graphic: Business Wire)
    “OpenFold-Multimer and SoloSeq are particularly useful for designed proteins that don't exist in nature.
  • Previous work in protein LLMs, primarily out of Meta AI, has produced a series of valuable LLM standalone models and the ESMFold structure model, which pairs ESM-family LLMs with OpenFold for structure prediction.

INTRODUCING AHNU®, FOOTWEAR FOR THOSE WHO LIVE ONE STEP AHEAD

Retrieved on: 
Martedì, Marzo 5, 2024
Sequence, Engineering, PEBA, UGG, Life

GOLETA, Calif., March 5, 2024 /PRNewswire/ -- AHNU®, a division of Deckers Brands (NYSE: DECK), launches today and introduces the star of its inaugural capsule, the Sequence 1 sneaker. Guided by the fusion of performance and aesthetic, AHNU enters the market with the introduction of timeless designs that feature cutting-edge technologies crafted for all-day wear and catered to those who live one step ahead.

Key Points: 
  • Guided by the fusion of performance and aesthetic, AHNU enters the market with the introduction of timeless designs that feature cutting-edge technologies crafted for all-day wear and catered to those who live one step ahead.
  • Every pair of AHNU sneakers reflects the belief that style and performance can coexist harmoniously.
  • Embracing innovative materials and processes, AHNU is dedicated to fusing the benefits of high-performance technologies with timeless styles.
  • We are committed to pushing the boundaries of materials, innovation, and design to bring the next great solution in footwear to the world.

Genetic Health Service Provider, Panacea, Launches to Make Whole Exome Sequencing Accessible to Consumers Without Insurance Barriers

Retrieved on: 
Mercoledì, Febbraio 28, 2024
PALM, Breast cancer, Dahlia, Sequence, BRCA, Risk, Health, Ovarian cancer, CLIA, Ashkenazi Jews, Exome sequencing, Disease, Science, Mutation, CAP, Insurance, Cancer, Vaccine

PALM BEACH, Fla., Feb. 28, 2024 /PRNewswire/ -- Panacea, the one-stop-shop for genetic health services making potentially life-saving testing accessible for consumers, today announced its nationwide* commercial availability, without needing to visit a doctor or receive approval from insurance.

Key Points: 
  • The problem is that current guidelines for doctors to order genetic tests, and for insurance to approve it, are missing about half of the people with genetic mutations.
  • "I had my exome sequenced with Panacea, even though I was not a candidate for testing based on today's medical guidelines.
  • This further inspired me to make clinical-grade whole exome sequencing more accessible, so everyone can make informed decisions about their future."
  • For more information on Panacea or on whole exome sequencing, please visit seekpanacea.com .

Champions Ascension Announces Alpha Event with $15,000 in Cash and Prizes

Retrieved on: 
Giovedì, Febbraio 15, 2024
Sequence, Follow, Blockchain, Emperor, UTC, UGC, Grand Bazaar, RPG, GAME, Web3, PC, Communication, Element, Ecosystem, AAA, Arena, PLAYER, Alpha, Video game

LOS ANGELES, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Champions Ascension, the popular arena-based, gladiatorial combat game by Rough House Games, announced today a week-long event from February 16th to February 23rd to celebrate its Alpha launch.

Key Points: 
  • "What we've developed with Champions Ascension is nothing short of a breakthrough in the arena fighter genre.
  • The Emperor's Legendary Crystals Event will feature $15,000+ in cash and prizes and is free to play.
  • Players earn tickets by fighting in the Arena and can exchange tickets for Raffle entries on the Champions Ascension website.
  • Winners will be announced on Champions.io and X (formerly Twitter) and the Champions Ascension Discord.